Diabetologia

Clinical and Experimental Diabetes and Metabolism

Organ of the European Association for the Study of Diabetes (EASD)

Volume 18 Number 5 May 1980

Editorial

K. G. M. M. Alberti
References Rationalised **351**

Originals

D. Q. Borsey, J. Dawes, D. M. Fraser, C. V. Prowse, R. A. Elton, B. F. Clarke
Plasma Beta-thromboglobulin in Diabetes Mellitus **353**

G. D. O. Lowe, J. M. Lowe, M. M. Drummond, S. Reith, J. J. F. Belch, C. M. Kesson, A. Wylie, W. S. Foulds, C. D. Forbes, A. C. MacCulsh, W. G. Manderson
Blood Viscosity in Young Male Diabetics with and without Retinopathy **359**

A. H. Barnett, S. M. Stubbs, A. M. Mander
Management of Premature Labour in Diabetic Pregnancy **365**

F. I. R. Martin, G. B. Wyatt, A. R. Griew, M. Haurahella, L. Higginbotham
Diabetes Mellitus in Urban and Rural Communities in Papua New Guinea. Studies of Prevalence and Plasma Insulin **369**

F. T. Lester
Ketoacidosis in Ethiopian Diabetics **375**

D. R. R. Williams, W. P. T. James, I. E. Evans
Dietary Fibre Supplementation of a 'Normal' Breakfast Administered to Diabetics **379**

M. Tesone, R. M. Oliveira-Filho, L. Biella de Souza Valle, J. C. Calvo, J. L. S. Barañao, V. G. Foglia, E. H. Charreau
Androgen Receptors in the Diabetic Rat **385**

P. Rösen, K. Schrör
Increased Prostacyclin Release from Perfused Hearts of Acutely Diabetic Rats **391**

J. C. Hutton, W. J. Malaisse
Dynamics of O_2 Consumption in Rat Pancreatic Islets **395**

Y. S. Kim, I. Jatoi, Y. Kim
Neonatal Macrosomia in Maternal Diabetes **407**

R. Rasch
Prevention of Diabetic Glomerulopathy in Streptozotocin Diabetic Rats by Insulin Treatment. Albumin Excretion **413**

J. P. Ashby, D. Shirling
Evidence for Priming and Inhibitory Effects of Glucose on Insulin Secretion from Isolated Islets of Langerhans **417**

R. W. Stevenson, T. I. Tsakok, J. A. Parsons
Matched Glucose Responses to Insulin Administered Subcutaneously and Intravenously. Evidence for Subcutaneous Inactivation of Insulin **423**

Letters to the Editor

S. R. Bloom
What's Wrong with Freedom? **427**

J. M. Conlon
The Glucagon-like Polypeptides – A Reply **428**

Organization Section **429**

Subscription Information

Volumes 18 and 19 (6 issues each) will appear in 1980. The price of each volume is DM 174,– or US $ 97.–. Information about obtaining back volumes and microform editions is available upon request.
North America: Subscription rate: $ 207.80, including postage and handling. Subscriptions are entered with prepayment only. Orders should be addressed to: Springer-Verlag New York Inc., Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094, Telephone (201) 348-4033, Telex 125994.
Japan: Subscription rate: DM 376,– including postage (surface airmail lifted) and handling. Orders can either be placed with your bookdealer or sent directly to: Springer-Verlag, Heidelberger Platz 3, D-1000 Berlin 33.
All Other Countries: Subscription rate: DM 348,– plus postage and handling. Orders can either be placed with your bookdealer or sent directly to: Springer-Verlag, Heidelberger Platz 3, D-1000 Berlin 33. Members of the European Association for the Study of Diabetes, the American Diabetes Association and the International Diabetes Federation are entitled to reduced rates. Please inquire about them with the publisher.

Indexed in Current Contents

Springer International

Diabetologia – ISSN 0012–186X DBTGAJ 18(5) 351–430 (1980)

For the stable, maturity-onset diabetic patient when diet alone has failed.

An effective choice to help control blood sugar

- ☐ Single or multiple dosing
- ☐ Two tablet strengths
- ☐ Documented bioavailability
- ☐ Severe hypoglycemia uncommon, but may occur*
- ☐ Twenty years of clinical use

Orinase®

tolbutamide, USP, Upjohn

0.25 and 0.5 Gm tablets



Therapeutic flexibility & dependability

Contraindications:
Orinase (tolbutamide) alone is not effective in juvenile or growth-onset diabetes nor in unstable brittle diabetes where insulin therapy is required.

Orinase tablets should not be used in diabetes complicated by acidosis, ketosis, or coma, or when a history of repeated bouts of acidosis or coma is obtained, in the presence of other acute complications such as fever, severe trauma, or infections, nor in patients with severe renal insufficiency. Insulin is indicated in these circumstances.

Pregnancy Warning: The safety and usefulness of *Orinase* during pregnancy has not been established. Animal studies have demonstrated feticidal and teratogenic effects. *Orinase* is not recommended for the pregnant diabetic, and should be used cautiously in women of childbearing age.

Precautions: Diagnostic and therapeutic measures necessary for optimal control with insulin are also necessary with *Orinase*. The patient on *Orinase* must be fully instructed about the nature, complications, and necessary personal measures needed to maintain control of the disease.

Caution: Very close observation, and careful adjustment of dose are necessary when: insulin is withdrawn during the trial period in order to avoid ketosis, acidosis, and coma; thiazide diuretics are administered, since they may aggravate the diabetic state and increase tolbutamide requirement, temporary loss of control, or even secondary failure; treating patients with impaired hepatic and/or renal function and debilitated, malnourished, or semistarved patients to avoid severe hypoglycemia; and treating patients with severe trauma, infection, or surgical procedures where temporary return to insulin or addition of insulin may be necessary. Beta-blocking agents reduce response to tolbutamide.

Patients must be under continuous medical supervision, and during the initial test period should communicate with the physician daily, and during the first month report at least once weekly for physical examination and definitive evaluation. After a month, examinations are recommended monthly or as indicated. Ketonuria, increased glycosuria, unsatisfactory lowering or persistent elevation of blood sugar, or poor clinical response indicate nonresponsiveness to *Orinase*. *Orinase* does not obviate the need for maintaining standard diet regulation. In treating mild asymptomatic diabetic patients with abnormal glucose tolerance, glucose tolerance tests should be obtained at 3-6 month intervals. *Orinase* is not an oral insulin or a substitute for insulin and must not be used as sole therapy in juvenile diabetes or in diabetes complicated by acidosis or coma where insulin is indispensable.

***Adverse Reactions:** Severe hypoglycemia, though uncommon, may occur and may mimic acute neurologic disorders such as cerebral thrombosis. Certain factors such as hepatic and renal disease, malnutrition, advanced age, alcohol ingestion, and adrenal and pituitary insufficiency may predispose to hypoglycemia. Certain drugs such as insulin, sulfonamides, oxyphenbutazone, salicylates, probenecid, monamine oxidase inhibitors, phenylbutazone, bishydroxycoumarin, and phenyramidol may prolong or enhance the action of *Orinase* (tolbutamide) and increase risk of hypoglycemia. *Orinase* long-term therapy has been reported to reduce RAI uptake without producing clinical hypothyroidism or thyroid enlargement. High doses are mildly goitrogenic in animals. Photosensitivity reactions, disulfiram-like reactions after alcohol ingestion, and false positive tests for urine albumin have been reported.

Although usually not serious, gastrointestinal disturbances (nausea, epigastric fullness, and heartburn) and headache appear to be dose related and frequently disappear with reduction of dose or administration with meals. Allergic skin reactions (pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions) are transient, usually not serious, and frequently disappear with continued administration. *Orinase* should be discontinued if skin reactions persist. Reports indicate that long-term use of *Orinase* has no appreciable effect on body weight.

Orinase appears to be remarkably free from gross clinical toxicity. Crystalluria or other renal abnormalities have not been observed, incidence of liver dysfunction is remarkably low, and jaundice has been rare and cleared readily on discontinuation of drug (carcinoma of the pancreas or other biliary obstruction should be ruled out in persistent jaundice).

Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, pancytopenia, and hepatic porphyria and porphyria cutanea tarda have been reported.

How Supplied: *250 mg Tablets* – bottle of 100. *0.5 Gram Tablets* – bottles of 50, 100, 200, 500 or 1000, Unit-Dose packages of 100, and Unit-of-Use packages of 30.

For additional product information, see your Upjohn representative or consult the package insert.

Upjohn

MED B-7-S